Here are the 10-K annual reports from Century Therapeutics, Inc. (IPSC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow IPSC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IPSC filings page.
Century Therapeutics is a biotechnology company developing off-the-shelf allogeneic cell therapies from induced pluripotent stem cells (iPSCs) for type 1 diabetes, autoimmune diseases, and cancer. Its platform combines iPSC reprogramming, CRISPR gene editing, proprietary Allo-Evasion™ immune cloaking, and in-house scalable manufacturing.
The lead program, CNTY-813, is an iPSC-derived beta islet replacement therapy using Allo-Evasion™ 5.0, aiming for durable glycemic control in type 1 diabetes without chronic immunosuppression. CNTY-308 is a CD19-targeted CAR-iT cell candidate for B-cell-mediated diseases, while CNTY-101 is a CD19 CAR-iNK product with six gene edits being evaluated in the CARAMEL Phase 1/2 investigator-sponsored trial in systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis.
The company emphasizes deep process and analytical know-how, cryopreservation, and a flexible multi-product facility in New Jersey. It supports its platform with extensive licensing and collaboration agreements, including Fujifilm Cellular Dynamics, iCELL, and Catalent, plus a broad patent estate around iPSCs, differentiation, Allo-Evasion™ technology, and safety switches. As of June 30, 2025, voting stock held by non-affiliates had an aggregate market value of $212,506,473, and as of February 28, 2026 there were 179,722,750 common shares outstanding.